		1636
TRANSMITTAL NOV 0 1 2004 FORM (to be used for all correspondence after initial form Total Number of Pages in This Submission Fee Transmittal Form	Examiner Name Attorney Docket Number ENCLOSURES (Check all that	O8/958,570 October 28, 1997 Gregory, Richard J. 1636 Guzo, David 016930-000921US After Allowance Communication to Technology Center (TC) Appeal Communication to Board
Amendment and Communication Under 37 CFR 1.821-1.825 After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addr Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks The Commissioner is a Account 20-1430.	of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information
Firm or Individual name Signature Date Signature Signature Signature October 27, 2004		EY, OR AGENT . No. 48,006
	itents, P.O. Box 1450, Alexandria, VA 2231	Service with sufficient postage as first class mail in an

NOV 0 1 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 016930-000921US

Client Ref. No.: 3005 Customer No.: 20350

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on /0/27/0

TOWNSEND and TOWNSEND and CREW LX

By:_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GREGORY et al.

Application No.: 08/958,570

Filed: October 28, 1997

For: RECOMBINANT ADENOVIRAL VECTOR AND METHODS OF USE

Confirmation No. 3556

Examiner:

Guzo, David

Art Unit:

1636

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

<u>AND</u>

AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action, mailed August 27, 2004, Applicants submit that the computer-readable form in the instant application is identical with the Substitute Sequence Listing submitted for Application No. 08/328,673 on February 15, 2000. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form submitted for Application No. 08/328,673 as the computer-readable form for the instant application. The information in

Appl. No. 08/958,570 Amdt. dated September 30, 2004 Reply to Office Action of August 27, 2004

the paper copy of the Substitute Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Abstract begin on page 4 of this paper.

Remarks begin on page 4 of this paper.